» Articles » PMID: 28003437

Editor's Highlight: Prospective Analyses of Volatile Organic Compounds in Obstructive Sleep Apnea Patients

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2016 Dec 23
PMID 28003437
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Various volatile organic compounds (VOCs) are known to be toxic. Although exhaled VOC patterns change in obstructive sleep apnea (OSA) patients, individual VOC profiles are not fully determined. The primary outcome was VOC characterizations; secondary outcomes included their relationships with sleep and clinical parameters in OSA patients. We prospectively examined 32 OSA patients with an apnea-hypopnea index (AHI) ≥ 15 by full polysomnography, and 33 age- and sex-matched controls without obvious OSA symptoms. Nine severe OSA patients were examined before and after continuous positive airway pressure (CPAP) treatment. By applying a method which eliminates environmental VOC influences, exhaled VOCs were identified by gas chromatography (GC)-mass spectrometry, and their concentrations were determined by GC. Exhaled aromatic hydrocarbon concentrations (toluene, ethylbenzene, p-xylene, and phenylacetic acid) in the severe OSA groups (AHI ≥ 30) and exhaled saturated hydrocarbon concentrations (hexane, heptane, octane, nonane, and decane) in the most severe OSA group (AHI ≥ 60) were higher than those in the control group. Exhaled isoprene concentrations were increased in all OSA groups (AHI ≥ 15); acetone concentration was increased in the most severe OSA group. Ethylbenzene, p-xylene, phenylacetic acid, and nonane concentrations were increased according to OSA severity, and correlated with AHI, arousal index, and duration of percutaneous oxygen saturation (SpO2) ≤ 90%. Multiple regression analyses revealed these 4 VOC levels were associated with the duration of SpO2 ≤ 90%. Isoprene and acetone decreased after CPAP treatment. OSA increased some toxic VOCs, and some correlated with OSA severity. CPAP treatment possibly ameliorates these productions.

Citing Articles

GC-MS-based metabolomics of volatile organic compounds in exhaled breath: applications in health and disease. A review.

Bajo-Fernandez M, Souza-Silva E, Barbas C, Rey-Stolle M, Garcia A Front Mol Biosci. 2024; 10:1295955.

PMID: 38298553 PMC: 10828970. DOI: 10.3389/fmolb.2023.1295955.


The State of the Art on Graphene-Based Sensors for Human Health Monitoring through Breath Biomarkers.

Moura P, Ribeiro P, Raposo M, Vassilenko V Sensors (Basel). 2023; 23(22).

PMID: 38005657 PMC: 10674474. DOI: 10.3390/s23229271.


Analysis of the volatile organic compounds of epidural analgesia-ameliorated metabolic disorder in pregnant women with gestational diabetes mellitus based on untargeted metabolomics.

Sana S, Lv Y, Chen G, Guo L, Li E Front Endocrinol (Lausanne). 2023; 14:1009888.

PMID: 36864845 PMC: 9970997. DOI: 10.3389/fendo.2023.1009888.


Urine and Fecal H-NMR Metabolomes Differ Significantly between Pre-Term and Full-Term Born Physically Fit Healthy Adult Males.

Deutsch L, Debevec T, Millet G, Osredkar D, Opara S, Sket R Metabolites. 2022; 12(6).

PMID: 35736470 PMC: 9228004. DOI: 10.3390/metabo12060536.


Production, Storage Stability, and Susceptibility Testing of Reuterin and Its Impact on the Murine Fecal Microbiome and Volatile Organic Compound Profile.

Castellani C, Obermuller B, Kienesberger B, Singer G, Peterbauer C, Grabherr R Front Microbiol. 2021; 12:699858.

PMID: 34394042 PMC: 8361477. DOI: 10.3389/fmicb.2021.699858.